Only the 3 ASX announcements that arrived after the close of the ASX market, on Friday..
Suspension has been lifted and its all go for a Monday morning restart.
Going to be an interesting day for sure.
Printable View
Only the 3 ASX announcements that arrived after the close of the ASX market, on Friday..
Suspension has been lifted and its all go for a Monday morning restart.
Going to be an interesting day for sure.
Judging by the interest on HC there are a lot of people suddenly waking up to the company's prospects.
SP was at 9.9c prior to suspension.
Preopen may confirm the rising interest with a lot of jostling for position.
Direct rejected my sell order as out of market, it will be interesting to see what happens this morning.
Today's rise is truly hair raising.
Boom. Well done holders (I'm not) but very happy if something turns into a success.
9.9 to 31 cents 23 million shares changed hands
About time.
Suspended today , something about a dodgy deal !!
Back in action with 6 million in the kitty from a placement cap raise.
More to come on Covid antibody test purchases and distribution.
Watch this one this week
Yes, on the 30th.
4C out today and doesnt look too bad considering the circumstances.
Plenty in the kitty and China starting to get back to normal business with Evolis.
Japan still looks to break even and the Wondfo Antibody tests look as if they are the real deal.
Tests being sold to the medical market in Australia.
Interesting they have set up their lab to do further research on the Coronavirus antibody test results.
And all in cooperation with the Aus Govt.
And now on Saturday QVC USA launched Evolis on their TV shopping channel
So that is QVC China, USA, Germany and Japan which has been the only one contributing revenue up to now.
Testing in America showed their tests were ok , only four tests were deemed adequate in the study i saw somewhere and theirs was one of them. More likely that their fancy American partner store Neiman Marcus has filed for bankruptcy, so they may have unpaid bills.
There is a problem with antibody testing in general. They are OK when infection rates are high, but become less useful if rates of infection are low.
https://covidtestingproject.org/ has information on CDY's test compared to others.
What is the news article they refer to in regards to the suspension?
There is a story in SMH today, can't link to it, but you should be able to find it easily.
https://www.npr.org/sections/health-...-miss-the-mark
https://stocknessmonster.com/announc...asx-2A1230742/
Not a good announcement at all. Down nearly 30%. Glad I stayed on the sidelines
I had this one a few years ago. Unfortunately, a pattern emerged with each announcement being about the great things that were just around the corner. After a while I lost confidence in management's ability to deliver for shareholders and moved on.
Trading halt , hope this one isn't as long as the last
https://www.businessnewsaus.com.au/a...-research.html
Much the same with a bit more detail
https://cellmid.com.au/wp-content/up...s-activity.pdf
Todays 4C
Just a taste
• Record revenue and consumer health sales in Q4: Revenue for the group in Q4FY2020 was $3.06 million (up 115% on pcp). This is the highest revenue to date in any one quarter and the highest ever quarterly consumer health revenue of$2.88 million (up 107% on pcp).• Stable full year on year results: Total FY2020 revenue of $8.511 million remained stable despite COVID-19 related economic disruption (up 2% on pcp). The Company remained resilient to the effects of the pandemic and consumer health revenue also remained stable at $7.40 million (up 1% on pcp).• New distribution channels continue to perform well: In FY2020, sales revenue in Australia was up 45% yoy and in the USA up 51% yoy. New ecommerce retailers and television shopping performed strongly during FY2020 compensating for closed brick-and-mortar retail in Australia and the USA.
But wait, there's more!
Salon distributor servicing 40,000 hair salons in the NE United States. Thats right, 40 thousand.
https://cellmid.com.au/wp-content/up...in-the-USA.pdf
'significant revenue growth to the US business from 2HFY2021'
Sounds all good but sellers have since piled on the downward pressure. Money flow looks to be heading out...
I took a small position in this just to remind me to follow it. Total punt. 40,000 points of sale can't be all bad.
Company seems to have a few tentacles flapping about.
Very very interesting link.
https://www.linkedin.com/pulse/targe...-jamal-alqasem
Definitely in the right ballpark for CDY midkine antibodies
Up to date Summary of the situation with Cellmid
Cellmid continues ecommerce momentum with strong FY2020 results despite economic disruption
Snapshot
The company has focused on ecommerce channels during the COVID-19 pandemic for its range of evolis hair care products but has also found a new revenue stream in SARS-CoV-2 tests for medical practitioners.
https://static2.proactiveinvestors.c...1057617791.jpg
Quick facts: Cellmid Limited
Price: 0.11 AUD
ASX:CDY
Market: ASX
Market Cap: $13.78 m
Follow
9. Mar20. Apr22. Jun20. Jul17. Aug0.10.20.30.4024MZoom1m3m6m1yFromFeb 26, 2020ToAug 26, 2020Up to dateHighcharts.com
View company profile
Cellmid Limited (ASX:CDY) reached record revenue in quarter four of FY20 with new distribution channels across Australia, Asia and the USA performing well,
The company reported revenue of $3.06 million, up 115% on the previous corresponding period, with total FY2020 revenue of $8.511 million despite COVID-19 related economic disruption.
During the quarter, Cellmid secured access to and/or supply of a broad range of SARS-CoV-2 tests, including antibody and nucleotide tests as well as laboratory-based and point of care (POC) assays.
The company submitted the Wondfo POC test to the Doherty Institute for validation where, in the most relevant period of 14+ days following the onset of symptoms, it was shown to have the equal highest sensitivity of the tests reviewed so far.
Cellmid received the first commercial shipment of 12,000 Wondfo POC tests on April 14, 2020, and sold around 1,500 tests to medical practitioners since.
The impact of these sales on FY20 results has not been material, but as the pandemic is expected to persist for many months (if not years) Cellmid will continue to seek out opportunities for SARS-CoV-2 testing in Australia and overseas.
Distribution agreements
Cellmid signed an exclusive distribution agreement with Immunodiagnostics Limited (IMD) Hong Kong for laboratory-based, quantitative Enzyme Linked Immunosorbent Assays (ELISAs) and a point of care serology test for SARS-CoV-2 for Australia and New Zealand.
In addition, authorisation from Guangzhou Wondfo Biotech Co Ltd (SHE:300482) has been extended for Australia Application Pty Ltd to be a distributor of the Wondfo SARS-CoV-2 antibody test in Australia until December 30, 2020.
Consumer health revenue
The company reported highest-ever quarterly consumer health revenue of $2.88 million during the quarter – an increase of 107%, with the total for FY20 sitting at $7.4 million.
New ecommerce retailers and television shopping performed strongly during FY20 as retail channels started to open with Japan up 114% to $2.35 million, Australia up 103% to $409,000 and the US up 44% to $129,000.
This was a strong result, especially in the absence of bricks-and-mortar retail activity in Australia and the USA for 3-4 months during the pandemic.
https://www.proactiveinvestors.com.a...ero%20JPEG.jpg
The company continues to grow distribution channels for its evolis productsAustralian and Asian demand
Strong quarter four revenue of $2.35 million in China was primarily the result of the QVC Today’s Special Value (TSV) event and the reopening of the Chinese export of Lexilis branded FGF5 inhibitor products and Jo-Ju in April 2020, following three months of lockdown.
Consumer health sales in Australia were up 45% for the year to $1.44 million with pharmacy wholesalers (API) and e-commerce representing the most significant channels.
Television shopping channel (Openshop) has delivered increasing revenue in Australia but despite the growth in e-commerce and TV shopping, the COVID-19 pandemic had a negative impact during quarter four - particularly with the delay of the Priceline experiential marketing launch.
Cellmid signed a trading agreement last year for its the evolis Professional anti-ageing hair care products to be available in 400 Priceline stores as well as on priceline.com.au.
While the launch was delayed, digital marketing launch activities commenced in July 2020, however, in-store events have been postponed again most recently due to the resurgence of the pandemic.
US ecommerce revenue
Consumer health sales in the US were up 51% in FY20 to $626,000 and up 44% in quarter four to $129,000 showing that, while business remains affected by the severity of the pandemic locally, ecommerce sales through retailers such as Bloomingdales, Saks and Macy’s are continuing.
Cellmid launched its evolis Professional products on Amazon (USA) in June 2020 and orders from other pure ecommerce retailers (such as Dermstore) have been regular during the quarter.
Notably, the company’s most significant retail customer in the USA, Neiman Marcus, has started to open its stores, placing orders to restock the evolis products and recommencing ecommerce activities throughout June.
Looking forward, the company expects ongoing ecommerce revenue growth, recently signing an agreement (via its wholly-owned US subsidiary Advangen LLC) with Tru Beauty Concepts Inc. for the exclusive distribution of its évolis products in salons.
Tru Beauty currently services 40,000 salons in 11 states in the northeast of the US and also has a partnership with wholesale ecommerce hub, Salon Interactive, which hosts individual salon websites, making premium hair care products available to clients of participating salons, even if they are not physically open due to the COVID-19 pandemic.
So Miner, what say you. Is it going lower after todays announcement or are we about to see bottom? Long time holder, very much down on investment. You seem endlessly optimistic on CDY , what comes when lyramid etc are spun out?
Its very hard to say what will happen, Cammo.
My thoughts are that if there is any substantial value in Midkine and it is sold off we would end up with a very cashed up and profitable Cellmid.
If there is a partnering agreement then presumably we would all have a share in whatever transpires.
I think we are about to find out in pretty short order with all the resignations, promotions.
All seems very upbeat and the SP is responding (sort of).
Might stop some of the bleating on HC
Cheers
Miner
As best as I can establish at this point it would appear that the spinoff of Lyramid involves a new asset called an exclusive licence to access all (maybe) or some (probably)of the Midkine patents which will be retained by the company.
This leaves CDY in control of their IP and takes the operational side, midkine research out of the equation.
If someone wants to participate in developing midkine related clinical trials or further research they will have to go through Lyramid who will make arrangements presumably if the up front or royalties meet CDY requirements.
With this happening ( if it happens) CDY would be able to concentrate on their Hair and beauty products without a bunch of distraction while retaining their rights to any developments in midkine.
Given that CDY was profitable in all markets, Japan, USA and Australia, with Evolis in September this could develop nicely from here.
Cellmid has nailed a 10 year agreement for its beauty products in SE asia including China.:)
https://hotcopper.com.au/threads/ann.../?source=email
Ill bring this up to date in due course. Its more to provide a reference point as the PEB thread seems to be showing some interest
https://cellmid.com.au/investors/asx...announcements/
Well the best I can ascertain from 30mins reading about what CDY has been up to this year, is that the board seems to have no idea what they are doing.
Really?
https://cellmid.com.au/wp-content/up...Newsletter.pdf
Have fun.
Thanks Minerbarejet, appreciate the link.
So it seems like they acknowledge the business has been a bit of a Frankenstein are are trying to align the business to execute on its growth strategy. The covid testing sounds like a mis-step this year though?
Any idea what the company might be able to sell Lyramid for? IP is great, but only if monetized effectively so perhaps they won't be able to get a good price.
We have it on pretty good authority that the Lyramid divestment as planned involves a licence to access CDY retained Patents relating to MK in various fields but not including the hair technology.
So while the MK side of things goes off into a separate company, not participating in the CDY balance sheet apart from upfront payments and royalties accruing to CDY, the focus can be mainly on Evolis.
The range of applications with MK is overwhelming because a company involved in melanoma studies and applications would most likely not be interested in osteoporosis or glioblastoma as an addon
If nothing comes of the divestment then CDY will retain everything as it is, so its hardly a fire sale or something that has to be dispensed with.
Until the Covid crisis is all done and dusted it will remain to be seen whether their foray into Covid Tests was a good idea or not
Thanks Minerbarejet.
OK, well I dipped my toes into this today with a very small initial position with profits from another trade. (It will make sure I pay attention to this stock!)
With a MCAP of $14M there's really not much room for downside. If they can crack the Chinese market with the evolis range then anything that comes from Lyramid is an added bonus.
Appreciate your comments- have a lovely festive season.
Good shot, mate.
As you say it cant really go much lower and there is a huge upside.
You have done well to get in at this point.
Make sure you get the emails from the company, I reckon there will be a few from now on.
All the best to you and others over this coming season
I too welcome you Longhaul.
The company is kicking some serious goals and profit may not be too far away.
Here is a link to their entry into China at TMall which could be massive not to mention all the other regions they are entering.
https://evolis.tmall.hk/shop/view_sh...7d5e09bcb93def
Cellmid website has just the leader page available and 404 not found on everything else for a couple of days that I know of.
Well worth keeping an eye on this when it resumes.
I suspect a major revamp is underway.
Three directors buying in but off market.
Website is back up - seems Lyramid is no longer present there so divestment may be taking place as planned or is about to.
This has the potential for a nice little jump in SP soon I think.
MCAP is pretty low, they have a bit of cash on hand, and I think on the whole things are about as positive as they ever have been.
And Directors seem positive and have skin in the game which is nice to see.
September had all three sources, Japan ,Australia and the US cashflow positive and the rate increasing.
China is added to Australia as is Europe in the meantime
If Sept had all three positive it would seem likely that this last quarter is in the Black given all the activity.
Any cash accruing from the unverified Lyramid divestment would help as well.
53 competition entries - still time for the 2021 competition - go cdy
Yeh - nah.
Soon as I put in an entry with CDY in it nothing will happen
Since July the company has been selling the newly developed Jo Ju skin and eye care range on Cosme one of the largest cosmetic sites in Japan (ranked inside top 750 websites in all of Japan and top 8,500 websites globally) and it appears to be selling well and getting very good reviews especially the eye cream.A three product range a serum, lotion and eye cream.
Reviews are still coming in this year so I feel they may be turning over a good amount of stock.
https://cosmeet.cosme.net/product/se...%83%93%83P%83A
I always struggle with distribution agreement announcements, they always lack the detail I like. Margins and a full cost center breakdown. Don't worry, I understand why this information isn't given, it just annoys me that investors miss out on some of the important details.
Any thoughts on the cap raise?
I have to admit it caught me by surprise given there was talk of being profitable very soon and already having 4.5 million in the bank.
I hope good decisions are being made how the money is spent to get this thing moving. I still believe in the company, I think they have a good product, and the share price right now I don't believe reflects the potential. Having said that, the management need to show results within the next year. I do like the fact that several directors/board have a decent amount of shares and said they are supporting the cap raise. Let's see, I'll support this one and have even asked for additional.
CDY reminds me a little of WDT or BLT...potentially a good product but selling it is far from easy!
Good decisions have been made all along it seems despite a lot of palaver to the contrary.
Nobody would have anticipated their MK research leading to a skin care range that is claimed to be twice as effective as hyaluronic acid based compounds which seems to be the current approach from most of the major cosmetic companies.
Having the patents for the MK formulas should be a considerable revenue generator if a Major picks up on it.
This will slot in nicely with the hair care treatments.
The cap raise is to facilitate the launch of these products in the Chinese market and elsewhere.
May well be a very good move on your part.
At 8 cents what could possibly go wrong?
I got some more as well, more as an antidilutional tactic and this information regarding MK involvement has come to light after the offer closed.
Rights issue shortfall completely oversubscribed to where they issued more and it still wasnt enough.
I somehow got the additional 200,000 I wanted. All in all was a lot of support for the cap raise, and after costs it's over 4 million bucks.
Spend it well please.
Very confident the Company will succeed and do well in the future, though a little patience will be required.
A bit of research recently along with another poster has discovered that Advangen ( owned by Cellmid) has brought out a number of new products in the Japanese, Cambodia, Chinese, markets.
They include not only the hair care range but also a skin care range that utilises MK (midkine) in the formula.
MK is known for its effect on collagen and elastin so it will be interesting to see if the claimed twice as good as hyaluronic acid based products stands up.
Looks like Helena Rubenstein all over again to me.
And we know how that turned out.
Shareprice in a steady decline.
I thought it would hold at around 7.5 but wrong I am.
Lots of bad sentiment between China and OZ at the moment, perhaps that has an impact due recent expansion attempts there.
I'm hoping we will see something positive soon! In the meantime the balls are firmly on the chopping block with another top up...how many times I've been told not to average down...and yet here we go again!
Worry ye not
CDY has today divested its Lyramid branch.
This may appear as a fire sale , etc.
It is not.
It has been planned for 2 years.
CDY will retain the rights to all their Midkine patents and licence them out to an outfit called Provelmare when they wish to advance various Midkine technologies.
Initial result is 500,000 in the bank and no further input from CDY to Lyramid in ongoing expenses
Any requirement from Provelmare will require CDY approval.
It seems Provelmare was set up to do this
Whats not to like in that?
Agreed this is a good step and will allow funds to be focused on sales growth.
Another 500k always helpful.
And not too long ago the company was selling a limited range of products in Japan and Australia only.
Look at it now. Truely global with an ever increasing foot print.
http://research.iress.com.au/IDS/old...091850000&ppv=
Held since 2010 but my 35 cent shares are looking super ****e right now. Maria sucks.
I can't imagine it can go much lower, but I said that at 7.5c.
I also bought more at 6.7 and 6.3.
They have heaps of cash now and many sales channels so time for action and good news and this puppy might just fly....
With the best part of 10 million in the bank, reduced expenses with selling the midkine physical assets but not the valuable patents, several new products about to hit the market and a market cap of 12mill it would appear to be a tad undervalued at 6.3/ 6.4c AUD.
Three things to watch for are:
A deal via Lyramid/Provelmare for access to a patent.
A profitable quarter which appears imminent given a boost from the Lyramid sale 500,000,
Plus YTD R&D expenses attributable Jan to April paid by Lyramid as part of the deal.
Reduced expenses from April to June by not having Lyramid and its personnel to manage.
Plus a major QVC Japan Todays Special Value in Japan in June that usually kicks out 1m
Several novel products arriving in the skincare range.
This is not financial advice.
Do your own research.
cellmid.com.au is a good place to start for those unfamiliar with the company and what it is doing.
Especially the investor presentations of late.
Have been monitoring TMall and now have an account with them so I can see what is happening on the sales front as they publish monthly average sales figures for the products they sell. At the moment the Jo Ju shop is off line for paperwork reasons for want of a better word. Nothing bad just the process of getting things going.
Anyhow when the Jo Ju shop was up for the initial promotional work one item being the Jo Ju Red which retails around $200 clocked up nearly 4000 sales which is around $800,000 retail. It is on the favourite / watch list of over 10,000 customers. Go figure.
The basic Evolis pharmacy range products are clocking up on average over 100 sales a month and appears to be increasing.
Plus excellent reviews.
Again go figure the potential of China.
All supposition on my part here but my gut feeling is that when the Jo Ju shop reopens the new Jo Ju Red Ex product, that has just been released on QVC Japan creating a record 1.3 million dollar sales record, will be released in China.
The new Jo Ju Red Ex as well as having the FGF5 inhibiting component has a new formulation which enhances the FGF7 component which is important for initiating growth in nascent hair follicles. The FGF5 inhibiting component reduces hair fall and extends the life cycle of you hair. Possibly a ground breaking combination.
When this popped up on the forum today I decided to have a look into it. I went at looked at one of the studies they cite to back their product https://pubmed.ncbi.nlm.nih.gov/28280377/ and was somewhat amused reading the conflict of interest section. Someone might have already mentioned it but I had a little chuckle.
After a night of reflection I'm still at a loss to understand why this conflict of interest of the above link would cause your smiles and chuckles.
Having said that we could all use a few these days.:)
Lots of new products either on their way or being planned.
Still loading up at these prices.
The Jo Ju Red and Lexilis products are now up and running big time on Taoboa which is another branch of Tmall. There are multiple shops selling the products in Beijing, Shanghai as well as other regions / towns in China. Some shops display how much stock they have on offer. One Beijing stockist of the Jo Ju Red triple pack has 9764 items in stock and is on the favourite / watch list of 784 people. One shop selling the Lexilis Scalp Lotion has 20,000 items in stock and is on the favourite list of over 2,000 people. Excellent reviews for product too.
I think China is on the verge of exploding.
Great work, Tsuba
Takes a bit of skill to find out that sort of information.
Looks like a world beater to me especially when the new product comes out
Thank you.
One of the Lexilis sellers has 550 customer feedback comments. That is significant in such a short time much more than other products. I actually think China is really kicking into gear.
Judging by the lack of response both here and on the market perhaps it is time to get the Advangen site up for a look at what is going on in Japan
There is quite a substantial range for Men and Women and they seem to be showing up more and more throughout Asia
https://www.shop-advangen.com/
(Advangen is a wholly owned subsidiary of Cellmid).
Bit of a China update for everyone interested.
China has generated, in a relatively short time frame, more and when I say more I mean SIGNIFICANTLY more customer feedback reviews from sales of Jo Ju, Lexilis and Evolis than every other outlet like Amazon and including Japan added together. As an example the Reverse Shampoo on Amazon with feedback totalling 139 and only 15 written reviews is the largest non Chinese figure. One Lexilis item in one of the many Chinese outlets has 573 reviews going back to about March this year and about 260 of those reviews are written also very good reviews. Some reviews also made yesterday.
One review from a repeat customer talks about taking advantage of the event. So I think QVC type sales days maybe going down.
Food for thought.
CDY's market cap is currently $9,371,528.
Cash on hand at 30th June was $6,727,764 and since received $1,374,483 taking cash to $8,102,247.
Revenue from continuing operations was $5,816,351.
They manage to have negative cash flow from operations of $4,114,150 and their year end loss was $3,710,527.
To just break even will require a miracle of biblical proportions.
........................................2021...... .....2020.......2019.........2018.......2017..
Revenue and Other Income 6,819,839 8,547,715 8,347,184 6,834,924 5,560,121
Operating Profit / (Loss) (3,221,986) (4,108,789) (3,042,031) (2,714,117) (4,022,577)
Loss after income tax (3,386,632) (4,907,296) (5,909,557) (3,732,615) (4,482,273)
Yes history is not on their side with $18,685,758 of losses in the past 5 years.A considerable amount.
Look forward to watching future performance,or non performance from the sidelines.?.lol
In order to clarify or elucidate on a somewhat vague post on my behalf I will attempt to bring an up to date summary on the current position with Cellmid to the fore.
Cellmid is a biotech company that has spent years developing a Midkine based technology to a PreClinical level.
This has been licensed out to an outfit called Provelmare Holdings who have purchased the right to exclusive access to the Patents owned by Cellmid.
These are considerable not only in their scope but value as well and will require a fee to be paid for access.
We await developments.
At one point Pacific Edge was granted the right on the payment of royalties to include a Midkine component to their, since established as successful, CxBladder tests. Unfortunately the havoc and delays caused by a completely unrealistic, dissonant, USA medical fraternity and the CMS resulted in much less than expected revenues to Cellmid before the patent expired.
On that note Pacific Edge would do well to pay out Cellmid for all tests done up to the expiry date. That includes all the unpaid for CMS tests that are still in negotiation.
The tests were utilized with MK as a component therefore payment is due
We can give them some time at the current interest rates.
We await developments
About halfway through this scenario it became apparent to Cellmid that Pacific Edge were not going to make much impression to the royalties inflow, despite their best efforts, and that remedial measures were needed to continue Cellmids growth.
This entailed the shifting of focus accompanied by Shareholder dissonance towards further Cap raises from the planned Stage 3 Clinical Trial Midkine side to a more subdued Preclinical status for a few Midkine applications and a larger focus on the recently acquired Advangen Hair Loss treatment company.
Note this as it is critical.
In February of this year Cellmid announced that they had devised and patented an aptamer that specifically hits the FGF5 gene and no other FGF gene.
The FGF5 gene is responsible for hair loss and its inhibition gives the appearance of hair growth.
The FGF7 gene that actually promotes growth has historically been hit by the same inhibitor, be it botanical or chemical and worldwide in its application.
In a lot of instances unknowingly and without scientific validation.
To hit the FGF5 gene specifically 100% without affecting the FGF7 will give Cellmid a patent approved leg up over the others comparable to going from a high jump to a pole vault.
We await developments.
Hi Miner, this gene which gives the appearance of growth. What does that mean? Is there measurable growth or not?
Have messaged Miner for you. I could give you an answer but will let him have first dibs.
In the mean time here is some more news for those interested.
April this year the Lexilis brand has been supplied to 26 Loft stores in Japan. Loft is a very big chain that is usually situated in the busiest trendyest parts of town.
Here is the Lexilis website.
Pretty flash.As does the product look.
http://advangen.co.jp/contents/lexilis/
For Airedale
The FGF5 gene is the gene that activates hair loss at the end of the cycle.
An FGF5 inhibitor such as Cellmid's Evolis stops that hair loss from happening.
By retaining more hairs in situ for longer there is therefore an appearance of growth.
From what I can gather it would seem that this approach in itself is a bit of a double edged sword in that when some of the compounds being used to stop the hair fall is applied it also stops the FGF7 gene from activating dormant hair follicles to some extent. Hence the need for more specificity
It would appear that Cellmid/Advangen, through much ongoing research, have found and have patented a means of attacking and inhibiting the FGF5 gene specifically and thereby lessening any influence on the FGF7 growth process at the same time.
I think it is currently being added to the company's extensive range of products.
Another piece of the puzzle I have just found this morning
https://www.nature.com/articles/s41598-021-82350-w
It would appear that FGF5 aptamer inhibitors may also work on cancer cells.
A lot of research going on out there
We await developments
Thanks Miner.
Interestingly the main Lexilis shop I am monitoring in China has had ten reviews already this month. The Chinese are really into social media as they love putting up photos of the product and photos of their hair progress. They quite often mention that they have ensured that the product is “ authentic “. Word will spread very quickly because of their love of telling friends about their new hair regime.
Big things happening with this company if you dig a little bit.
New products like the innovative Supplement coming out in October as well as many more I feel.
One of the shops selling Lexilis in China.
The cumulative comments is where you can get a handle on turn over.
These shops on Taoboa have lots of stats presented. With some things you need an account to see what is happening.
https://item.taobao.com/item.htm?spm...ucket=4#detail
https://hotcopper.com.au/threads/ann...st_id=56104694
Massive news.:)
Market reaction has seen the share price rise to 6.1 cents today,with 6.6mil shares traded so far today..
Here is a link to the latest news regarding the acquisition of BLC by Cellmid.:)
Complete with a pro forma analysis that will help with understanding of the deal involved.
https://hotcopper.com.au/threads/ann.../?source=email
Good to see the CEO buy a few shares on market the other day.
https://hotcopper.com.au/threads/ann.../?source=email
The CEO may very well regard her company as the most undervalued stock on the ASX.
Given that from tomorrow they start accumulating BLC revenue (and expenses presumably) and the company will more or less double in size once the SH give the deal the OK at the end of October, I would tend to agree with her.
By then a fairly substantial Q1 CDY result to the end of Sept should also be known which may add a bit of spice to it.
N BRIEF: Roquefort plans reverse takeover of Australian drug maker
Roquefort Investments PLC - London-based investor in early-stage medical biotechnology businesses ...
29 September, 2021 | 2:12PM
Roquefort Investments PLC - London-based investor in early-stage medical biotechnology businesses - Enters non-binding term sheet with Provelmare Holding SA for reverse takeover of 100% of Lyramid Ltd in GBP1 million cash-and-share deal. Australian business Lyramid holds an exclusive worldwide licence for 37 midkine-based therapy patents. To fund transaction, Roquefort will conduct placing to raise up to GBP3 million.
"The respective teams at Roquefort Investments and Lyramid believe the midkine global patent portfolio has significant unrealised value that can be unlocked through pre-clinical drug development utilising oligonucleotide drugs," says Chair Stephen West. "Due to recent progress in oligonucleotide drug development (for example, mRNA used in Pfizer and Moderna Covid-19 vaccines) there is an opportunity to progress the pre-clinical drug development stage rapidly and at a significantly lower cost than historical traditional methods."
an exclusive worldwide licence for 37 midkine-based therapy patents.
Lyramid has a licence to access these patents.
Cellmid CDY:ASX owns the patents and will be due royalties of at least 4% on any sales made.
From Pitt St research.
We believe CDY offers a compelling growth story driven by its differentiated product portfolio. As its products are clinically proven, they are efficacious due to the clear mechanism of action, namely inhibiting hair loss protein, FGF5. We believe this will build credibility with consumers and increase brand awareness and loyalty. Further, there doesn’t seem to be many competing products that are clinically validated in this segment. Thus, we think CDY has a strong value proposition, which we expect to drive market share gain in the medium term.
We also expect near/medium term growth to be driven by:
1) new distribution partnerships,
2) launch of new products,
3) improved e-commerce capabilities, and
4) synergies the BLC acquisition.
Valuation of $0.21 -$0.30 per share
Lots to think about here at the moment.
They seem to have developed a system where the FGF5 gene takes care of the inhibiting of hair loss (patented) and another improvement that boosts the FGF7 gene for hair growth in the same mixture. They appear to have achieved this through the invention of an aptamer this year that targets the FGF5 gene specifically and nothing else.
This is fairly unique as far as I know. :)
Here is a link to the Pitt St research
https://static1.squarespace.com/stat...29501f70/16333
Everything you need to know. Pretty thorough. :)
Very thorough indeed,and interesting reading. Happy to be holding, despite the depressed share price recently.
Interesting new product being launched by CDY today at 2000 hours NZDST.
Well I suppose it will be interesting, they usually are.:)
Acquisition of BLC has been completed and CDY is now double the size it was.
A name change is on the cards....
The Company proposes to change its name from “Cellmid Limited” to “Anagenics Limited” which more accurately reflects the current and proposed future operations of the Company, its scientific origins and corporate ethos. The change of name will take effect from when ASIC alters the details of the Company's registration.The word Anagenics is derived from the Greek “anagennitheis”, which means regenerate, regrow, grow. The first part of the word, anagen, describes the growth phase of the hair follicle, the key target for the Company’s FGF5 inhibitor hair technologies. The Company’s FGF5 inhibitor technology extends this ‘anagen’ or growth phase of the hair cycle, thereby the name Anagenics will honour the health and beauty tech origins of the Company. Further, the word also represents longevity, growth and regeneration as concepts which are all connected to wellness, youth, and beauty; these are the targeted indications for the Company’s current and future products and services. The word Anagenics is strongly descriptive of the Company’s objective to create an information and advice driven marketplace for scientifically validated health, wellness, and longevity brands.